Table 1 Baseline characteristics of the study Population.

From: Lung tissue T cells are activated in chronic obstructive pulmonary disease with non-small cell lung cancer patients

 

COPD

non-COPD

 
 

(n = 39)

(n = 68)

p

Age, years

    

0.0068**

   Median

73

69

 

   Range

52−89

38−87

 

Sex, n (%)

    

<0.0001*

   Male

33

− 84.6

31

− 45.6

 

   Female

6

− 15.4

37

− 54.4

 

Smoking status, n (%)

    

0.0023*

   Current or ex-smoker

34

− 87.2

40

− 58.8

 

   Non-smoker

5

− 12.8

28

− 41.2

 

Spirometry

     

   % FEV1/FVC

63.9 ± 4.9

79.6 ± 5.4

<0.001**

   FEV1 (% of the predicted value)

81.8 ± 13.6

99.0 ± 17.7

<0.001**

Histology, n (%)

    

0.2939*

   Adenocarcinoma

23

− 66.7

50

− 73.5

 

   Squamous cell carcinoma

13

− 23.3

15

− 22.1

 

   Others

3

− 10

3

− 4.4

 

Stage (UICC-8th edition), n (%)

    

0.2210*

   I

18

− 46.1

44

− 64.7

 

   II

14

− 35.9

13

− 19.1

 

   III

6

− 15.4

10

− 14.7

 

   IV

1

− 2.6

1

− 1.5

 

Drugs administered, n (%)

     

   Inhaled bronchodilator

24

− 61.5

6

− 8.8

<0.0001*

   Inhaled steroids

4

− 10.3

0

0

0.0159*

   Oral steroids

1

− 2.6

2

− 2.9

1.0000*

Adjuvant therapies

     

   Radiotherapy

0

0

1

− 1.5

1.0000*

   Chemotherapy

3

− 7.7

16

− 23.5

0.0635*

      CDDP+VNR

1

− 2.6

5

− 7.4

 

      CBDCA+S-1

0

0

1

− 1.5

 

      UFT

2

− 5.1

10

− 14.7

 

Interstitial Lung Disease

    

1.0000*

   Yes

9

− 23.1

15

− 22.1

 

   No

30

− 76.9

53

− 77.9

 
  1. Data are presented as the mean ± SD unless otherwise indicated.
  2. CDDP, cisplatin; VNR, vinorelbine; CBDCA, carboplatin; UFT, tegafur/uracil; S-1, tegafur/gimeracil/oteracil.
  3. *Fisher’s exact test.
  4. **Mann–Whitney U test.